LINK: "The findings, reported in the Journal of Neuroscience, suggest that sulfasalazine, a drug on the market for nearly 40 years, can reduce tumor size by interfering with the cancer cell's ability to make the brain chemical glutathione. "

Without glutathione, tumor cells are more susceptible to attack by the body's natural defenses.

“Clinical trials could begin very quickly, since a clinically approved drug that can be delivered orally is already available,” said Harald [cq] Sontheimer, Ph.D. professor of neurobiology and director of the UAB Civitan International Research Center.

University of Alabama at Birmingham
701 20th St. S., AB 1320
Birmingham, AL 35294-0113
United States uab.edu/news